Independent
Tenure on this board
0.5 yrs
Also a director at
Scienture Holdings Inc (SCNX)Crown Reserve Acquisition Corp I (CRAC)Datameds Ai Inc (MEDS)
5 nominees · 4 ballot items.
Election of five directors; ratification of Suri & Co. as auditors; non-binding advisory approval of named executive officer compensation (say-on-pay); approval of the Amended and Restated 2021 Omnibus Stock Incentive Plan to increase shares and add an annual evergreen provision.
To elect five directors to the Board, each to serve for one year or until their successors are elected and qualified.
To ratify the appointment of Suri & Co., Chartered Accountants as the Company’s independent registered public accounting firm for the year ending December 31, 2026.
The proposal asks shareholders to ratify the Board’s appointment of Suri & Co. as the company’s independent registered public accounting firm for the year ending December 31, 2026. Management is seeking approval to provide stockholders an opportunity to ratify this selection, although ratification is not required by the bylaws. Context includes a recent dismissal of the prior auditor (Sadler, Gibb and Associates, LLC), and the Board’s discretion to change auditors even if ratified. The Board recommends a vote FOR, arguing this appointment is in the Company’s and stockholders’ best interests. The recommendation is supported by the Audit Committee’s oversight of auditor selection, pre-approval of fees, and the expected presence of a Suri representative at the annual meeting to respond to questions. Given the prior auditor dismissal and the relatively small audit fees disclosed for 2025, analysts should consider auditor transition risks, continuity of audit quality, and the Audit Committee’s processes when evaluating the merits of ratification.
To approve, on a non-binding advisory basis, the compensation of the named executive officers as disclosed in the proxy statement.
This management proposal requests an advisory (non-binding) approval of the compensation paid to the company's named executive officers, as disclosed in the proxy statement. Management seeks shareholder feedback on overall pay philosophy and implementation; the vote is advisory and will not bind the Board but will inform future compensation decisions. The Board and Compensation Committee support the proposal, emphasizing alignment of pay with company performance and retention objectives; they will consider the vote results when making future pay decisions. Given the company's status as a smaller reporting company and recent executive turnover and large equity grants tied to transactions, analysts should weigh whether disclosed pay practices align with performance, retention needs, and governance best practices when forming a view on this proposal.
To approve the Amended and Restated Equity Incentive Plan to increase the maximum number of shares by 3,000,000 and add an annual evergreen provision of 5% starting January 1, 2027.
Management's proposal asks shareholders to approve an amended and restated version of the company's 2021 Omnibus Stock Incentive Plan that increases the available share pool by 3,000,000 shares and adds an annual evergreen increase of 5% of outstanding shares starting January 1, 2027. Management is seeking shareholder approval to ensure sufficient share availability to grant equity awards for retention, recruitment, and to align employee incentives with shareholder value. The proposal contains governance implications — significant potential dilution, an evergreen provision that will increase the share reserve annually unless curtailed by the Board, and a substantial increase relative to the current remaining pool. The Board recommends a vote FOR, citing the need to have sufficient shares for 2026 issuances and ongoing grants. Analysts evaluating this proposal should consider current dilution metrics, recent equity grants to executives (including large post-transaction grants), the company's compensation practices, and whether the evergreen mechanism is appropriate governance-wise or requires guardrails to limit dilution or link increases to performance or shareholder approval.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | HRT FINANCIAL LP | 0.04% | 22,683 | $43K |
| 2 | Virtu Financial LLC | 0.04% | 22,005 | $42K |
| 3 | CITADEL ADVISORS LLC | 0.02% | 11,110 | $21K |
| 4 | MORGAN STANLEY | 0.02% | 10,000 | $19K |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 0.01% | 7,614 | $14K |
| 6 | BlackRock, Inc. | 0.01% | 3,019 | $6K |
| 7 | MORGAN STANLEY | 0.00% | 1,165 | $2K |
| 8 | VANGUARD FIDUCIARY TRUST CO | 0.00% | 1,018 | $2K |
| 9 | WELLS FARGO COMPANY/MN | 0.00% | 960 | $2K |
| 10 | JONES FINANCIAL COMPANIES LLLP | 0.00% | 715 | $1K |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.